No abstract

q3w with an incidence ratio of 1.13 (0.19 e 4.70). Both groups had a high proportion of patients with low grade toxicity (fatigue, pruritus, rash; q6w 46%, q3w 42%). Table: 1821P Group characteristics (median, range) q6w q3w Age (yr) 72 (33-90) 72 (42-91) Follow-up time (months) 6.2 (0.1-11) 13.2 (2.5-44) Treatment cycles given 4 (1-10) 14 (3-57) Total treatment duration (patient-months) 391 1175.Conclusions: To our knowledge, this is the first analysis of toxicity data for a q6w Pembrolizumab regime. Incidence of CSirAEs is low. Low grade toxicity was common and over the course of treatment could impact quality of life. Despite limited number of events, the q6w schedule does not appear to lead to significantly higher toxicity and should be used in view of the reduced visit burden to patients and health services.Legal entity responsible for the study: the authors.

No abstract

No abstract

No abstract